糖尿病肾病中的新型标志物——现状与展望
Novel Markers in Diabetic Kidney Disease-Current State and Perspectives.
作者信息
Piwkowska Agnieszka, Zdrojewski Łukasz, Heleniak Zbigniew, Dębska-Ślizień Alicja
机构信息
Laboratory of Molecular and Cellular Nephrology, Department of Molecular Biotechnology, Faculty of Chemistry, Mossakowski Medical Research Institute Polish Academy of Sciences, University of Gdansk, 80-308 Gdansk, Poland.
Department of Nephrology, Transplantology, and Internal Medicine, Faculty of Medicine, Medical University of Gdansk, 80-308 Gdansk, Poland.
出版信息
Diagnostics (Basel). 2022 May 11;12(5):1205. doi: 10.3390/diagnostics12051205.
Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease. Along with the increasing prevalence of diabetes, DKD is expected to affect a higher number of patients. Despite the major progress in the therapy of DKD and diabetes mellitus (DM), the classic clinical diagnostic tools in DKD remain insufficient, delaying proper diagnosis and therapeutic interventions. We put forward a thesis that there is a need for novel markers that will be early, specific, and non-invasively obtained. The ongoing investigations uncover new molecules that may potentially become new markers of DKD-among those are: soluble α-Klotho and proteases (ADAM10, ADAM17, cathepsin, dipeptidyl peptidase 4, caspase, thrombin, and circulating microRNAs). This review summarizes the current clinical state-of-the-art in the diagnosis of DKD and a selection of potential novel markers, based on up-to-date literature.
糖尿病肾病（DKD）是终末期肾病的主要病因。随着糖尿病患病率的上升，预计受DKD影响的患者数量会更多。尽管在DKD和糖尿病（DM）治疗方面取得了重大进展，但DKD的经典临床诊断工具仍然不足，导致诊断和治疗干预延迟。我们提出一个观点，即需要能够早期、特异性且非侵入性获取的新型标志物。正在进行的研究发现了一些可能成为DKD新标志物的新分子，其中包括：可溶性α-klotho和蛋白酶（ADAM10、ADAM17、组织蛋白酶、二肽基肽酶4、半胱天冬酶、凝血酶）以及循环微小RNA。本综述基于最新文献总结了DKD诊断的当前临床最新进展以及一些潜在的新型标志物。
Zotero 插件